SWOT Analysis for Alnylam Pharmaceuticals Inc

Add SWOT widget to your site/app

Price crossing above SMA20 today, and greater than SMA5
Consistent Highest Return Stocks over Five Years - Nifty500
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Annual Net Profits improving for last 2 years
Top Gainers
Stock with Low PE (PE < = 10)
Negative to Positive growth in Sales and Profit with Strong Price momentum

Price crossing above SMA20 today, and greater than SMA5

Consistent Highest Return Stocks over Five Years - Nifty500

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Week

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

Annual Net Profits improving for last 2 years

Top Gainers

Stock with Low PE (PE < = 10)

Negative to Positive growth in Sales and Profit with Strong Price momentum

Momentum Trap (DVM)
Companies with High Debt
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Risky Value (DVM)
Low durability companies
Low Piotroski Score : Companies with weak financials
Stocks Underperforming their Industry Price Change in the Quarter

Momentum Trap (DVM)

Companies with High Debt

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Risky Value (DVM)

Low durability companies

Low Piotroski Score : Companies with weak financials

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Alnylam Pharmaceuticals Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Alnylam Pharmaceuticals Inc has 11 Strengths, 7 Weaknesses, 2 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Price crossing above SMA20 today, and greater than SMA5

Consistent Highest Return Stocks over Five Years - Nifty500

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Week

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

Annual Net Profits improving for last 2 years

Top Gainers

Stock with Low PE (PE < = 10)

Negative to Positive growth in Sales and Profit with Strong Price momentum

Momentum Trap (DVM)

Companies with High Debt

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Risky Value (DVM)

Low durability companies

Low Piotroski Score : Companies with weak financials

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks